SOPHiA DDM™ Trial Match Addendum

This SOPHiA DDM™ Trial Match Addendum ("Addendum") describes additional Services SOPHiA GENETICS will provide under the Purchase Agreement between: (i) SOPHiA GENETICS and (ii) the Customer (the "Purchase Agreement"). The SOPHiA GENETICS General Terms and Conditions ("Terms and Conditions") apply to these Services.

By confirming in writing the activation of a specific clinical trial in your account in the scope of SOPHiA DDM™ Trial Match service, Customer agrees to this Addendum.

Customer hereby represents and warrants that the representative confirming the activation of a specific clinical trial is dully authorized to represent the Customer and to enter into this Addendum.

Except as modified below, the terms of the Purchase Agreement shall remain in full force and effect and apply in respect of this Addendum.

RECITALS

a. SOPHiA DDM™ Trial Match is a pre-screening tool available for customers holding a SOPHiA DDM™ Platform account (the "Account") and using SOPHiA DDM™ Platform and network for their NGS analysis.

b. SOPHiA DDM™ Trial Match aims to facilitate the connection between hospitals, laboratories, and therapy development organizations with contract research organizations and other clinical trial sponsors to enhance patient access to clinical trials.

c. When SOPHiA DDM™ Trial Match services are activated for a specific clinical trial, it allows SOPHiA GENETICS to identify potentially eligible candidates for that clinical trial using specific genetic mutations and other eligibility criteria defined by the clinical trial sponsor and to refer Customer’s contact details to the clinical trial sponsors.

1. SOPHiA DDM™ TRIAL MATCH SERVICES - STEP-BY-STEP PROCESS

The following is a step-by-step description of the SOPHiA DDM™ Trial Match services:

STEP 1: By signing the Purchase Agreement, SOPHiA GENETICS is authorized to refer Customer to clinical trial sponsors (the “Sponsor”) and provide Sponsor with the contact details of Customer institution. In addition, SOPHiA GENETICS may conduct a statistical retrospective query on specific molecular profiles of interest to Sponsor and provide Sponsor with aggregated, anonymized, statistical data that is derived from the results of analysis performed by SOPHiA GENETICS and its Affiliates (i.e., Insights).

STEP 2: In this context, Customer and Sponsor may establish an agreement regarding Customer’s inclusion in clinical trials of interest. Once Customer receives confirmation of its clinical trial participation from Sponsor, Sponsor will provide a written notice to SOPHiA GENETICS confirming that Customer is a participant site in the clinical trial.

STEP 3: Following the notification received from Sponsor as described in Step #2, SOPHiA GENETICS will contact Customer regarding the activation of the relevant clinical trial. By confirming in writing the activation of a specific clinical trial, Customer authorizes SOPHiA GENETICS to access its Account for the sole purpose of identifying potentially eligible molecular profiles according to the parameters established for the clinical trial in question. Only employees who are bound by a confidentiality obligation and trained for these purposes will be allowed to do so, and SOPHiA GENETICS will at all times limit the number of individuals who may access the data to a standard that is reasonably necessary according to applicable law. More generally, SOPHiA GENETICS will process Customer Data only in accordance with the SOPHiA GENETICS’ General Terms and Conditions.

STEP 4: Following Step 3 confirmation from Customer, SOPHiA GENETICS will activate the alert to identify potentially eligible molecular profiles according to the parameters established for the clinical trial in question.
**STEP 5:** When a molecular profile is identified by SOPHiA GENETICS as matching for the clinical trial, SOPHiA GENETICS will communicate to Customer and Sponsor, by email, the following information:

- The SOPHiA DDM™ Platform identification number of the relevant molecular profile, which is a pseudonymized random number to allow the Customer to locate the profile accordingly;
- The date of the analysis performed through the SOPHiA DDM™ Platform associated with the relevant profile;
- The SOPHiA DDM™ Platform identification number of the relevant analysis, which is a pseudonymized random number to allow the Customer to locate the analysis accordingly; and
- The protein and relevant variant information identified as part of the analysis pertaining to the relevant profile.

No patient health information, or other personal data or information shall be communicated to Customer and Sponsor or any third party by SOPHiA GENETICS, without the prior written consent of Customer.

**STEP 6:** When Customer receives a notification as indicated in Step 5, the Customer may, in its sole and absolute discretion, choose to take the necessary steps toward the enrollment of the patient in the clinical trial. SOPHiA GENETICS is not involved and does not intervene in any way with the patient enrollment process.

2. **FREE OF CHARGE PRINCIPLE OF THE SOPHiA DDM™ TRIAL MATCH SERVICES**

SOPHiA GENETICS shall not request any additional remuneration from Customer for the performance of the SOPHiA DDM™ Trial Match Services.